細胞療法市場：細胞タイプ、治療タイプ、用途、エンドユーザー別-2025～2030年の世界予測

細胞療法市場は、2023年に86億6,000万米ドルと評価され、2024年には96億米ドルに達すると予測され、CAGR 10.93％で成長し、2030年には179億1,000万米ドルに達すると予測されています。

細胞療法再生医療における最先端のフロンティアは、損傷した組織や臓器を修復したり置き換えたりするために生きた細胞を投与することです。この治療法の適用範囲は、腫瘍学、神経学、整形外科学、心血管疾患など多岐にわたります。その必要性は、慢性疾患、遺伝性疾患、従来の治療では不十分な変性疾患に対する解決策を提供できる可能性があることにあります。最終用途セグメントには、臨床研究機関、病院、専門センターなどがあり、これらの治療法の開発、検査、応用に不可欠です。市場の成長要因としては、慢性疾患の有病率の増加、細胞ベースの研究の進歩、有利な規制の枠組みなどが挙げられます。最新のビジネス機会は、CAR-T細胞療法が特定のがんに対して主導権を握る個別化医療や、幹細胞細胞療法における用途の拡大など、進化するセグメントにあります。細胞開発プロセスの改善におけるAIと機械学習の採用も有望な展望です。しかし、複雑な規制状況、高い生産コスト、厳しいポリシーによる限定的な商業化などの課題が成長の可能性を抑制しています。また、倫理的な懸念や限定的な長期有効性データに起因する市場受容のためらいもあります。イノベーションは、スケーラブルな製造ソリューション、コスト削減、先進的臨床検査による安全性と有効性の確保に焦点を当てるべきです。企業は、研究の相乗効果のために学術機関との提携を模索することもできると考えられます。市場はダイナミックであり、急速な技術進化が顕著であるため、各社は変化する規制を機敏に遵守し続ける必要があります。成長機会は、医療インフラの整備とバイオテクノロジーへの投資が増加傾向にある新興国市場に存在します。さらに、一般大衆の認識と理解を向上させるための教育キャンペーンへの投資は、市場の受容性を高める可能性があります。成功するためには、利害関係者は技術革新と協調的イノベーションを活用しながら課題を克服し、世界中で細胞治療の採用と成功を推進しなければならないです。

市場力学：急速に進化する細胞療法市場の主要市場洞察を公開

細胞療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • バイオテクノロジー革新への政府投資の増加と細胞療法の承認率
  • 細胞療法サプライチェーンの改善
• 市場抑制要因
  • 幹細胞移植に関連する副作用
• 市場機会
  • がん治療におけるキメラ抗原受容体T細胞（CAR-T）療法の進展とESC（胚性幹細胞）とiPSC（人工多能性幹細胞）の使用
  • 神経疾患治療における幹細胞利用の増加
• 市場課題
  • 幹細胞使用に伴う倫理的問題と薬理学的問題

ポーターのファイブフォース：細胞療法市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：細胞療法市場における外部からの影響の把握

外部マクロ環境要因は、細胞療法市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：細胞療法市場における競合情勢の把握

細胞療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：細胞療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、細胞療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目セグメントを網羅した包括的な市場分析を提供しています。

1.市場の浸透度：産業主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • バイオテクノロジーの革新と承認率に対する政府の投資の増加細胞療法
    • 細胞療法サプライチェーンの改善
  • 抑制要因
    • 幹細胞移植に関連する副作用
  • 機会
    • がん治療におけるキメラ抗原受容体T細胞（CAR-T）療法の進歩とESC（胚性幹細胞）とiPSC（人工多能性幹細胞）の利用
    • 神経疾患の治療における幹細胞の利用増加
  • 課題
    • 幹細胞の使用に伴う倫理的問題と薬理学的問題
• 市場セグメンテーション分析
  • 細胞タイプ：治療用途の幹細胞の進歩
  • 治療タイプ：個別化医療における自己細胞療法の採用増加
  • 用途：細胞療法の皮膚科応用の進歩
  • エンドユーザー：病院やクリニックにおける疾病管理のための細胞療法の多様な用途
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境
• 顧客のカスタマイズ

第6章 細胞療法市場：細胞タイプ別

• イントロダクション
• 分化細胞
• 幹細胞

第7章 細胞療法市場：治療タイプ別

• イントロダクション
• 同種療法
• 自家療法

第8章 細胞療法市場：用途別

• イントロダクション
• 自己免疫疾患
• 皮膚科
• 筋骨格療法
• 腫瘍学

第9章 細胞療法市場：エンドユーザー別

• イントロダクション
• バイオテクノロジーと製薬企業
• 病院とクリニック
• 研究機関

第10章 南北アメリカの細胞療法市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の細胞療法市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの細胞療法市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Pluriが新しい細胞療法CDMO部門を立ち上げ
  • Max Healthcare、デリー首都圏のがん治療改善のためCAR-T細胞療法を開始
  • Bayer、世界規模で再生医療を推進するため、初の細胞療法製造施設を開設

企業一覧

• Athersys, Inc.
• Sartorius AG
• BioNTech SE
• Anterogen Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Novartis AG
• Thermo Fisher Scientific, Inc.
• Stempeutics Research Pvt. Ltd.
• Vericel Corporation
• JCR Pharmaceuticals Co., Ltd.
• Mesoblast Ltd.
• Castle Creek Biosciences, Inc.
• FUJIFILM Holdings Corporation
• Gilead Sciences, Inc.
• Stemedica Cell Technologies, Inc.
• Medipost Co., Ltd.
• Smith & Nephew PLC
• Bone Therapeutics SA
• NuVasive, Inc.
• Kolon TissueGene, Inc.
• Lonza Group Ltd.
• Astellas Pharma Inc.
• TegoScience
• Bristol-Myers Squibb Company

LIST OF FIGURES

• FIGURE 1. CELL THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. CELL THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY DIFFERENTIATED CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Cell Therapy Market was valued at USD 8.66 billion in 2023, expected to reach USD 9.60 billion in 2024, and is projected to grow at a CAGR of 10.93%, to USD 17.91 billion by 2030.

Cell therapy, a cutting-edge frontier in regenerative medicine, involves the administration of living cells to repair or replace damaged tissues and organs. The scope of this therapy spans applications in oncology, neurology, orthopedics, and cardiovascular conditions among others. Its necessity is driven by its potential to provide solutions for chronic diseases, genetic disorders, and degenerative conditions where traditional treatments fall short. End-use sectors include clinical research organizations, hospitals, and specialized cell therapy centers, all crucial for developing, testing, and applying these therapies. Market growth factors include increasing prevalence of chronic diseases, advancements in cell-based research, and favorable regulatory frameworks. The latest opportunities lie in evolving areas like personalized medicine, with CAR-T cell therapy leading the charge against specific cancers, and expanding applications in stem cell therapy. Adoption of AI and machine learning in improving cell development processes is another promising prospect. However, challenges such as complex regulatory landscapes, high production costs, and limited commercialization due to stringent policies restrain growth potential. There is also hesitancy in market acceptance stemming from ethical concerns and limited long-term efficacy data. Innovations should focus on scalable manufacturing solutions, reducing costs, and ensuring safety and efficacy through advanced clinical trials. Companies could explore partnerships with academic institutions for research synergies. The market is dynamic, marked by rapid technological evolution, necessitating players to remain agile and compliant with changing regulations. Opportunities for growth are present in developing markets where healthcare infrastructure advancements and investments in biotech are on the rise. Additionally, investing in educational campaigns to improve public perception and understanding could boost market acceptance. To succeed, stakeholders must navigate the challenges while leveraging technological and collaborative innovations to drive the adoption and success of cell therapies worldwide.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell Therapy Market

The Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
  • Improvements in Cell Therapy Supply Chain
• Market Restraints
  • Side Effects Related to the Stem Cell Transplant
• Market Opportunities
  • Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
  • Increasing Use of Stem Cells for the Treatment of Neurological disorders
• Market Challenges
  • Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues

Porter's Five Forces: A Strategic Tool for Navigating the Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell Therapy Market

A detailed market share analysis in the Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Athersys, Inc., Sartorius AG, BioNTech SE, Anterogen Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, Thermo Fisher Scientific, Inc., Stempeutics Research Pvt. Ltd., Vericel Corporation, JCR Pharmaceuticals Co., Ltd., Mesoblast Ltd., Castle Creek Biosciences, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Stemedica Cell Technologies, Inc., Medipost Co., Ltd., Smith & Nephew PLC, Bone Therapeutics SA, NuVasive, Inc., Kolon TissueGene, Inc., Lonza Group Ltd., Astellas Pharma Inc., TegoScience, and Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Cell Type, market is studied across Differentiated Cell and Stem Cell.
• Based on Therapy Type, market is studied across Allogenic Therapies and Autologous Therapies.
• Based on Application, market is studied across Autoimmune Diseases, Dermatology, Musculoskeletal Therapies, and Oncology.
• Based on End-User, market is studied across Biotechnology and Pharmaceutical Companies, Hospitals and Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
    • 5.1.1.2. Improvements in Cell Therapy Supply Chain
  • 5.1.2. Restraints
    • 5.1.2.1. Side Effects Related to the Stem Cell Transplant
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
    • 5.1.3.2. Increasing Use of Stem Cells for the Treatment of Neurological disorders
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues
• 5.2. Market Segmentation Analysis
  • 5.2.1. Cell Type: Advancements in stem cells for therapeutic applications
  • 5.2.2. Therapy Type: Increasing adoption of autologous cell therapies for personalized medicines
  • 5.2.3. Application: Advancements in dermatological applications of cell therapies
  • 5.2.4. End-User: Diverse applications of cell therapies in hospitals and clinics for disease management
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Cell Therapy Market, by Cell Type

• 6.1. Introduction
• 6.2. Differentiated Cell
• 6.3. Stem Cell

7. Cell Therapy Market, by Therapy Type

• 7.1. Introduction
• 7.2. Allogenic Therapies
• 7.3. Autologous Therapies

8. Cell Therapy Market, by Application

• 8.1. Introduction
• 8.2. Autoimmune Diseases
• 8.3. Dermatology
• 8.4. Musculoskeletal Therapies
• 8.5. Oncology

9. Cell Therapy Market, by End-User

• 9.1. Introduction
• 9.2. Biotechnology and Pharmaceutical Companies
• 9.3. Hospitals and Clinics
• 9.4. Research Institutes

10. Americas Cell Therapy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cell Therapy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cell Therapy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Pluri Launches New Cell Therapy CDMO Division
  • 13.3.2. Max Healthcare Launches CAR-T Cell Therapy to Improve Cancer Care in Delhi-NCR
  • 13.3.3. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale

Companies Mentioned

• 1. Athersys, Inc.
• 2. Sartorius AG
• 3. BioNTech SE
• 4. Anterogen Co., Ltd.
• 5. Takeda Pharmaceutical Company Limited
• 6. Pfizer Inc.
• 7. Novartis AG
• 8. Thermo Fisher Scientific, Inc.
• 9. Stempeutics Research Pvt. Ltd.
• 10. Vericel Corporation
• 11. JCR Pharmaceuticals Co., Ltd.
• 12. Mesoblast Ltd.
• 13. Castle Creek Biosciences, Inc.
• 14. FUJIFILM Holdings Corporation
• 15. Gilead Sciences, Inc.
• 16. Stemedica Cell Technologies, Inc.
• 17. Medipost Co., Ltd.
• 18. Smith & Nephew PLC
• 19. Bone Therapeutics SA
• 20. NuVasive, Inc.
• 21. Kolon TissueGene, Inc.
• 22. Lonza Group Ltd.
• 23. Astellas Pharma Inc.
• 24. TegoScience
• 25. Bristol-Myers Squibb Company